Demo
BDX NYSE· Becton Dickinson & Co.
FundamentalsNews digest Peer analysis
Login
BDX NYSE· Becton Dickinson & Co.
Earnings report Q4 2023

BDX Reports Revenue Growth in Q1 2024

Segments of Revenue

Becton, Dickinson and Company (BDX) reported total revenues of $4.71 billion in the first quarter of 2024, reflecting a 2.6% increase compared to the same period in the previous year. The company's revenue growth was driven by strong sales in the Medical segment's Medication Delivery Solutions and Medication Management Solutions units, as well as in the Interventional segment's Urology and Critical Care unit. However, the first quarter revenues were unfavorably impacted by a decline in respiratory illness-related sales compared to the prior-year period.

Strengths

BDX demonstrated strength in its revenue growth, outpacing its spending in the first quarter of 2024. The lower selling and administrative expenses, as well as research and development expenses, as percentages of revenues, contributed to improved profitability. The company's management attributed the revenue growth to strong sales in key segments, indicating successful product offerings and market demand. Additionally, BDX's international revenues increased by 5.5%, showcasing its global presence and ability to capture market opportunities beyond the United States.

Challenges

BDX faced challenges in the first quarter of 2024, primarily due to a lower gross profit margin compared to the same period in the previous year. This decline was primarily attributed to unfavorable foreign currency translation. The company's respiratory illness-related sales decline also posed a challenge, impacting overall revenues. It is important for BDX to address these challenges and find ways to mitigate the impact on its financial performance.

Noteworthy

BDX's revenue growth in the first quarter of 2024 exceeded expectations, driven by strong sales in key segments. The company's ability to navigate the challenges posed by unfavorable foreign currency translation and respiratory illness-related sales decline is noteworthy. BDX's focus on innovation and market demand in its Medication Delivery Solutions, Medication Management Solutions, Urology, and Critical Care units contributed to its overall performance.

Summary

Becton, Dickinson and Company (BDX) reported a 2.6% increase in total revenues in the first quarter of 2024, driven by strong sales in key segments. The company's revenue growth outpaced its spending, resulting in improved profitability. BDX faced challenges with a lower gross profit margin due to unfavorable foreign currency translation and a decline in respiratory illness-related sales. However, the company's ability to address these challenges and capitalize on market opportunities internationally showcases its resilience. BDX's focus on innovation and market demand in its key segments contributed to its overall positive performance in the latest quarter.

Source documents

Form 10-Q  filed on Feb 01, 2024
123 pages scanned

Reference data

Company financials Q4 revenue 0
Analyst estimates Q4 EPS missed by 0.00%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.